AbbVie
AbbVie, Inc.
ImbruvicaLinzessVraylar
- Platform
- Beacon
- Start
- January 1, 2027
340B Rebate Model
Get ready for 340B rebate submissions in 2027.
HRSA has approved 10 manufacturers for the 340B rebate model starting January 1, 2027. Aventi prepares and submits your rebate claims to Beacon for every approved manufacturer.
One price: $750 per covered entity per month for 2027 rebate claims, in-house pharmacy medical claims submissions to Beacon, and 340B ESP/Truzo claims data.
Learn more about in-house pharmacy medical claims submissions to Beacon.
- 1Purchase
The covered entity buys the drug at a non-340B price instead of the 340B price.
- 2Submit
Claims data for eligible dispenses is submitted to show the drug qualified for 340B.
- 3Rebate
Once the data is validated, the manufacturer pays the 340B discount back as a rebate.
HRSA-approved
HRSA-approved 2027 rebate model manufacturers
On October 1, 2026, HRSA approved 10 manufacturers for the 340B Rebate Model Pilot Program, covering 21 selected drugs. Rebates start January 1, 2027, and claims data is submitted through Beacon within 45 days of dispense.
Amgen
Amgen, Inc.
EnbrelOtezlaOtezla XR
- Platform
- Beacon
- Start
- January 1, 2027
Astellas
Astellas Pharma US, Inc.
Xtandi
- Platform
- Beacon
- Start
- January 1, 2027
AstraZeneca
AstraZeneca Pharmaceuticals LP
Farxiga
- Platform
- Beacon
- Start
- January 1, 2027
Bristol Myers Squibb
Bristol Myers Squibb Company
EliquisPomalyst
- Platform
- Beacon
- Start
- January 1, 2027
Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc.
JardianceOfevTradjenta
- Platform
- Beacon
- Start
- January 1, 2027
GSK
GlaxoSmithKline (GSK)
Breo ElliptaTrelegy Ellipta
- Platform
- Beacon
- Start
- January 1, 2027
Merck
Merck Sharp & Dohme LLC
JanuviaJanumetJanumet XR
- Platform
- Beacon
- Start
- January 1, 2027
Pfizer
Pfizer Inc.
Ibrance
- Platform
- Beacon
- Start
- January 1, 2027
Teva
Teva Pharmaceuticals
AustedoAustedo XR
- Platform
- Beacon
- Start
- January 1, 2027
Last updated: October 2, 2026
Source: HRSA via AHA, Oct 1, 2026
Only these selected drugs move to rebates; all other drugs stay at upfront 340B pricing.
This is separate from the in-house pharmacy medical claims requirements tracker below.
Data updated 2026-10-02.The basics
What is the 340B rebate model?
1
Purchase
The covered entity buys the drug at a non-340B price instead of the 340B price.
2
Submit
Claims data for eligible dispenses is submitted to show the drug qualified for 340B.
3
Rebate
Once the data is validated, the manufacturer pays the 340B discount back as a rebate.
The rebate model changes when and how the 340B discount reaches you. It makes accurate, timely claims data central to getting paid.
Why now
Why covered entities need to be ready for 2027
On October 1, 2026, HRSA approved 10 manufacturers' plans for the 340B Rebate Model Pilot Program. The pilot starts January 1, 2027, and applies only to selected drugs for IPAY 2026/2027 on the CMS Medicare Drug Price Negotiation Selected Drug List.
Beacon, developed by Second Sight Solutions, already supports Medicare MFP validation and is now the IT platform for all 10 HRSA-approved rebate model plans, so rebate claims for every selected drug in the pilot flow through Beacon starting January 1, 2027.
Covered entities submit claims data through Beacon within 45 calendar days of dispense. Manufacturers must pay or deny within 10 calendar days of a completed submission.
The rebate equals WAC minus the 340B ceiling price on the date of dispense. Other drugs stay at upfront 340B pricing.
The rebate model doesn't replace 340B ESP or Kalderos TruZo. Only the selected drugs move to Beacon rebates, and covered entities still submit claims data to 340B ESP and Kalderos TruZo to meet other manufacturers' claims data requirements. Aventi's $750 per covered entity per month price covers those 340B ESP and TruZo submissions along with your rebate claims.
Reconciliation will not disappear under the rebate model. With a 45-day submission window and a 10-day pay-or-deny clock, covered entities already juggling multiple manufacturer portals, changing manufacturer requirements, staff capacity constraints and manual MTF claim downloads will need clean, submission-ready claims data and a way to track every rebate paid or denied.
How Aventi helps
How Aventi handles rebate submissions
Beacon-ready
Ready to submit 340B rebate claims to Beacon for the 2027 rebate model.
Submission-ready claims data
Real-time claim capture and precise eligibility matching keep every claim audit-ready.
340B ESP and Truzo (Kalderos)
Real-time 340B ESP integration and an API connection to Truzo, with automated ESP and TruZo submissions for both contract and in-house pharmacies.
Reconciliation and GFI tracking
Good Faith Inquiries submitted and tracked in one view, plus MFP reconciliation tools, negative balance management and duplicate discount monitoring.
Flat monthly pricing
$750 per covered entity per month covers rebate claims, in-house pharmacy medical claims submissions to Beacon, and 340B ESP/Truzo claims data.
Pricing
One simple price
$750 per covered entity per month
Includes
- 2027 340B rebate claim submissions
- In-house pharmacy medical claims submissions to Beacon (available now)
- 340B ESP and Truzo claims data submissions
Already an Aventi TPA client? All of this is included. The pricing above is for covered entities that use another TPA.
Manufacturer tracker
Manufacturers requiring in-house pharmacy claims data
A growing number of drug manufacturers now condition 340B pricing on claims data for drugs dispensed through a covered entity's own (in-house, entity-owned) pharmacy, not just contract pharmacies. The list below covers requirements we have verified against the manufacturer's published notice. Scope, covered products, state exemptions, and deadlines vary, so always review the full notice.
Last updated: October 1, 202616 manufacturers listed
Recent = effective on or after July 1, 2026.
Merck
RecentOctober 1, 2026Hospital and CH CEs: pharmacy and medical CLD for in-house pharmacy dispenses of Table 1 products via 340B ESP within 45 days.
Johnson & Johnson
RecentSeptember 15, 2026All CE types (except Ryan White Part B ADAPs): claims data for every 340B J&J dispense/administration regardless of location, via 340B ESP within 45 days (60 for listed products).
Genentech
RecentAugust 31, 2026Universal claims data: all CEs submit CLD for in-house pharmacy, outpatient facility, and CP dispenses/administrations via 340B ESP.
Boehringer Ingelheim
RecentJuly 6, 2026All CE types: pharmacy and medical claims data on 340B utilization filled at in-house pharmacies via 340B ESP within 45 days.
Novartis
RecentJuly 6, 2026All CEs: pharmacy and medical CLD for in-house pharmacy/entity-designated address dispenses of Novartis drugs via 340B ESP within 45 days.
GSK
RecentJuly 1, 2026All CE types: in-house and contract pharmacy claims-level data for all dispensed GSK products via 340B ESP within 45 days.
Sobi
RecentJuly 1, 2026All CEs: claims data for all 340B utilization (incl. in-house pharmacy dispenses) of Doptelet, Kineret, and Vonjo via 340B ESP within 45 days.
Sanofi
June 15, 2026Claims data (pharmacy and medical) for entity-owned (in-house) pharmacies for CAH, DSH, RRC, SCH, CH, and now children's and free-standing cancer hospitals.
Amgen
June 1, 2026All CE types: claims-level data for all 340B pharmacy and medical dispenses (in-house and CP), all products; healthcare visit and service claims data added Nov 15, 2026.
Biogen
June 1, 2026All CE types: pharmacy CLD for all 340B dispenses of specified products (Avonex, Plegridy, Tecfidera, Vumerity), incl. in-house, via 340B ESP.
UCB
June 1, 2026Hospital and grantee CEs with in-house pharmacies: all claim/dispensing data (pharmacy and medical) for 340B-priced drugs, entire portfolio, via 340B ESP within 45 days.
AstraZeneca
May 1, 2026Universal claims requirement: all CEs submit 340B pharmacy and medical claims, incl. in-house dispenses, for products in Attachment B, via 340B ESP within 45 days.
Bristol Myers Squibb
May 1, 2026All CEs: CLD for all 340B utilization of listed drugs from entity-owned pharmacies and designated CPs, within 45 days.
Novo Nordisk
April 1, 2026All CE types: claims-level data for all in-house pharmacy (and CP) 340B dispenses via 340B ESP within 45 days; annual in-house pharmacy certification.
Eli Lilly
February 1, 2026All CE types: pharmacy and medical CLD for all 340B dispenses (incl. in-house), entire portfolio, via 340B ESP within 45 days (60 days for listed products).
Exelixis
October 1, 2025Claims data for all 340B dispenses, including in-house pharmacy dispenses, via 340B ESP.
CE = covered entity; CP = contract pharmacy; CLD = claims-level data; CH = consolidated health center; CAH/DSH/RRC/SCH = hospital covered entity types.
This tracker is for general information only and is not legal advice. Manufacturer policies change frequently; confirm requirements in each manufacturer's current notice.
Aventi handles in-house pharmacy medical claims submissions
Aventi handles in-house pharmacy medical claims submissions to Beacon and 340B ESP and monitors manufacturer requirement changes for you, included in the $750 per covered entity per month price, even if Aventi isn't your TPA.
Or email Abi Romano directly at abi@aventihealth.com.
FAQ
340B rebate model questions
It is an approach where covered entities pay a non-340B price at purchase, submit claims data showing 340B eligibility, and receive the 340B discount afterward as a rebate, rather than receiving the discount up front.
The HRSA-approved 340B Rebate Model Pilot Program starts January 1, 2027. Covered entities must submit claims data to Beacon within 45 calendar days of dispense.
HRSA approved 10 manufacturers covering 21 selected drugs for a January 1, 2027 start through Beacon: AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GSK, Merck, Pfizer, Teva. Source: HRSA, October 1, 2026.
Yes. Aventi is Beacon-ready, built for HRSA's rebate model pilot, and also integrates with 340B ESP and Truzo (Kalderos).
$750 per covered entity per month covers 2027 340B rebate claim submissions, current in-house pharmacy medical claims submissions to Beacon, and 340B ESP and Truzo claims data submissions. Already an Aventi TPA client? All of this is included; the price is for covered entities that use another TPA.
No. Reconciliation will not disappear under the rebate model. Aventi tracks Good Faith Inquiries and provides MFP reconciliation tools in one view.
As of October 1, 2026, the following manufacturers require covered entities to submit 340B claims data for in-house (entity-owned) pharmacy dispenses, subject to each policy's scope and exemptions: Merck, Johnson & Johnson, Genentech, Boehringer Ingelheim, Novartis, GSK, Sobi, Sanofi, Amgen, Biogen, UCB, AstraZeneca, Bristol Myers Squibb, Novo Nordisk, Eli Lilly, Exelixis. Aventi handles in-house pharmacy medical claims submissions to Beacon and 340B ESP and monitors requirement changes, included in the $750 per covered entity per month price, even if Aventi isn't your TPA.